Barbara J. Gitlitz, MD, associate professor of clinical medicine, Keck Medicine, University of Southern California, discusses EGFR mutations in patients with lung cancer.
Gitlitz's case study highlights the exon 20 insertion, which is the third most common EGFR mutation. The first most common mutation is exon 19, and the second is the exon 20 mutation. Patients present with this exon 20 insertion, and they are resistant to the common EGFR tyrosine kinase inhibitor (TKI).
She stresses the importance of looking at the resistant mutation because while it still drives the cancer, the first and second generation EGFR inhibitors are not strong enough to inhibit the target.
Barbara J. Gitlitz, MD, associate professor of clinical medicine, Keck Medicine, University of Southern California, discusses EGFR mutations in patients with lung cancer.
Scott Evaluates Treatment Options for Hydroxyurea-Resistant Polycythemia Vera
March 28th 2024In a Community Case Forum event in partnership with the Washington State Medical Oncology Society, Bart Scott, MD, broke down various trials of hydroxyurea, ruxolitinib, and interferon in patients with polycythemia vera to assess outcomes such as hematocrit control and molecular response.
Read More
Roundtable Roundup: Surveying Oncologists on Endometrial Cancer Treatment
March 27th 2024Bhavana Pothuri, MD, and Krishnansu S. Tewari, MD, discussed the treatment options of a patient with advanced endometrial cancer and participants chose an immune checkpoint inhibitor to use for therapy.
Read More
Gertz Assesses Notable Adverse Events of Talquetamab for Relapsed/Refractory Multiple Myeloma
March 26th 2024During a Case-Based Roundtable event, Morie Gertz, MD, discussed the safety profile of talquetamab as a single agent and in combination with daratumumab in patients with relapsed/refractory multiple myeloma.
Read More
Repotrectinib Elicits an Intracranial Response in ROS1+ Advanced NSCLC
March 25th 2024During a Case-Based Roundtable® event, Christine, Bestvina, MD, discussed the intracranial responses to repotrectinib for patients with ROS1-psotive non–small cell lung cancer in the first article of a 2-part series.
Read More